Abstract
A paradoxical role for vascular COX-1 products in vasoconstriction and atherogenesis highlights it as a novel therapeutic target.
Funding Information
  • National Institutes of Health (R01-CA084572 R01-CA123055 P50-CA086306)
  • British Heart Foundation (FS/16/1/31699 RG/18/4/33541)
  • British Heart Foundation (RG/18/4/33541)
  • Phelps Family Foundation
  • Crump Family Foundation

This publication has 69 references indexed in Scilit: